Moderna, Tempus, and Merck partnered on the INTerpath-001 trial, which focuses on indications that are covered by Medicare.
2 reports, 2 independent
Updated Sep 7
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Moderna, Tempus, and Merck partnered on the INTerpath-001 trial, which focuses on indications that are covered by Medicare.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.The partnership between Moderna, Tempus, and Merck is advancing, requiring genomic sequencing for successful trials and eyeing the post-treatment MRD market.1 source
Moderna, Tempus, and Merck partner on INTerpath-001 trial for Medicare-covered indications.1 source